EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group

Timothy J Kirtek iD, Weina Chen iD, Jaryse C Harris, Adam Bagg, Kathryn Foucar, Wayne Tam, Attilio Orazi iD, Eric D Hsi, Robert P Hasserjian, Sa A Wang iD, David P Ng iD, Tracy I George und 6 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70116 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Timothy J Kirtek und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Leukemia, Myeloid, Acute, Mutation, Leukemia, Biphenotypic, Acute. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The World Health Organization (WHO) 5th Edition and International Consensus Classification (ICC) have continued to delineate more genetically defined acute leukemias. Both recognize genetic aberrations associated with myelodysplastic syndromes/neoplasms (MDS) as defining MDS‐related AML (AML‐MR). Mutations in RUNX1 are included in this category in the ICC, but not WHO. The current classifications are unclear on how acute leukemias with ambiguous lineage (ALAL), including those of mixed lineage (MPAL) and those without a defined lineage (AUL), should be categorized in the presence of such mutations. Our multi‐institutional study aims to determine the significance of RUNX1 mutation in ALAL compared to de novo AML. Newly diagnosed MPAL, AUL, and AML with RUNX1 mutations were collected. ALAL with MDS‐related cytogenetics, BCR::ABL1 , KMT2A rearrangements, or ZNF384 or BCL11b abnormalities were excluded. We analyzed 17 cases of ALAL and 71 cases of AML that met inclusion criteria. ALAL‐ RUNX1 and AML‐ RUNX1 showed overlapping mutational landscapes with frequent comutations in MDS‐associated genes. No ALAL‐ RUNX1 or AML‐ RUNX1 cases showed concomitant TP53 mutation. ALAL‐ RUNX1 had more bone marrow blasts and more karyotypic abnormalities; however, neither impacted survival, nor did RUNX1 variant allele frequency (VAF). Survival analysis revealed similarly poor outcomes between them. AML‐directed therapies and allogeneic hematopoietic stem cell transplant trended toward improved survival in ALAL‐ RUNX1; however, it did not reach significance. Our results suggest ALAL‐ RUNX1 is associated with younger age, higher blasts, and more karyotypic abnormalities, but has similar clinical and genetic features and outcomes to AML‐ RUNX1 . Our findings suggest, like other MR mutations, RUNX1 ‐mutated ALALs should be included within AML‐MR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitLeukemia, Myeloid, AcuteMutationLeukemia, Biphenotypic, AcuteHumansMaleAgedFemaleMiddle AgedAdultPrognosisAged, 80 and overMyelodysplastic Syndromes

Stichwörter der Autor:innen

AMLimmunophenotypemolecular geneticsmyelodysplastic syndromeoutcomes research

Substanzen

Core Binding Factor Alpha 2 SubunitRUNX1 protein, human

Autor:innen und Institutionen

  • University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • University of New Mexico, Albuquerque, New Mexico, USA.
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
  • Texas Tech University Health Science Center, El Paso, Texas, USA.

ORCID-Profile: Timothy J Kirtek, Weina Chen, Attilio Orazi, Sa A Wang, David P Ng, Min Shi, Xinmin Zhang, Daniel A Arber

Zitieren

APA

Kirtek, T. J., Chen, W., Harris, J. C., Bagg, A., Foucar, K., Tam, W., Orazi, A., Hsi, E. D., Hasserjian, R. P., Wang, S. A., Ng, D. P., George, T. I., Shi, M., Reichard, K. K., Symes, E., Zhang, X., Arber, D. A., & Weinberg, O. K. (2026). Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group. American Journal of Hematology. https://doi.org/10.1002/ajh.70116

Vancouver

Kirtek TJ, Chen W, Harris JC, Bagg A, Foucar K, Tam W, et al. Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group. American Journal of Hematology. 2026. doi:10.1002/ajh.70116

BibTeX
@article{Kirtek2026,
  author = {Kirtek, Timothy J and Chen, Weina and Harris, Jaryse C and Bagg, Adam and Foucar, Kathryn and Tam, Wayne and Orazi, Attilio and Hsi, Eric D and Hasserjian, Robert P and Wang, Sa A and Ng, David P and George, Tracy I and Shi, Min and Reichard, Kaaren K and Symes, Emily and Zhang, Xinmin and Arber, Daniel A and Weinberg, Olga K},
  title = {Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70116}
}
Kostenlos starten →